Mepolizumab treatment in patients with severe eosinophilic asthma.

By Hector Ortega, Mark C. Liu, I. Pavord, Guy Brusselle, J. Fitzgerald, A. Chetta, M. Humbert, Lynn E Katz, Oliver N. Keene, Steven W. Yancey and 6 more. New England Journal of Medicine, 2014

1,961 citations recorded by the source corpus.

Subfields: Physiology, Pulmonary and Respiratory Medicine, Sociology and Political Science

View Paper: https://www.semanticscholar.org/paper/12100b5c77ce39695df8c640e3516d88e654f08d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

1. A. Reiner
2. Yun Li

In Sociology and Political Science

1. Adam S. Butterworth

Citations in the corpus

• The Polygenic and Monogenic Basis of Blood Traits and Diseases (2020, background): “Interestingly, both IL5 and IL4 are current therapeutic targets for treating a number of allergic diseases (Chang and Nadeau, 2017); (Ortega et al., 2014).”
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis (2021, positive): “It has also been independently proven to be effective in eosinophilic asthma (51).”